SBC Medical Group Holdings, Inc. (SBC)
NASDAQIndustrialsConsulting ServicesSnapshot 2026-09-04
$4.12-3.74%
Close 2026-09-04 · 1-day change
NASDAQIndustrialsConsulting ServicesSnapshot 2026-09-04
QuarterlyIQ Insights · SBC
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Leverage AI-powered tools to expand clinic locations, increase average fees, and broaden service menus, driving sustainable revenue and EPS growth.
Stated in 2 of last 2 quarters. Q2 2026 revenue grew 13% year-over-year to $49 million, with net income up 335% to $11 million. The number of clinic locations increased by 34 to 287. Management's emphasis on AI-enabled service enhancements aligns with these growth metrics, indicating delivery on this priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Industrials names rated strong grew net income 67% of the time over the next year (vs 52% for the rest of the cohort, n=6958).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Strengthening our AI-enabled MSO platform drives growth across locations, fees, and service menu breadth.”
“We will further enhance our services through the utilization of AI to build a sustainable healthcare platform.”
Deepen domestic aesthetic dermatology brands and grow non-aesthetic medical business as a second growth engine, while expanding internationally.
Stated in 2 of last 2 quarters. Customer visits grew 10% year-over-year to 6.9 million as of June 2026, supporting management's focus on expanding multi-brand aesthetic and non-aesthetic medical businesses. The trajectory shows delivery consistent with stated growth ambitions.
“We will deepen our multi-brand strategy in aesthetic dermatology domestically and expand our non-aesthetic business.”
“We will continue to promote our multi-brand strategy in aesthetic dermatology and expand our non-aesthetic medical business.”
Maintain disciplined capital allocation with $184 million cash on hand to fund growth initiatives and sustain financial stability.
Stated in 2 of last 2 quarters. Cash and cash equivalents rose from $167 million in 2026-Q1 to $184 million in 2026-Q2, supporting management's commitment to disciplined investment. The financial data confirms a strong liquidity position consistent with this priority.
“With $184 million in cash and cash equivalents on hand, we will continue disciplined investment toward growth.”
“We have a strong cash position to support growth and capital deployment plans.”
Accelerate global growth through collaboration in the U.S. and expansion in ASEAN, anchored in Thailand.
Stated in 2 of last 2 quarters. Management emphasizes international expansion including U.S. collaboration and ASEAN growth. While specific financial metrics for international segments are not provided, the recurring focus indicates ongoing strategic priority.
“We plan to accelerate global growth through collaboration with OrangeTwist in the U.S. and ASEAN expansion.”
“We will strengthen our operational foundation in overseas markets including the U.S. and Asia.”
Continue strategic growth by expanding SBC's presence in the U.S. medical aesthetics market.
Over the trailing year it converted 0.62x of net income into operating cash flow. Historically, Industrials names rated fragile grew net income 48% of the time over the next year (vs 59% for the rest of the cohort, n=4997).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
10 material management or governance events in the past 24 months, led by M&A activity. Historically, Industrials names rated neutral grew net income 58% of the time over the next year (vs 56% for the rest of the cohort, n=3431).
Not investment advice. As of 2026-09-04.